AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.an2therapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | In-line → Underperform | Evercore ISI | |
| 8/9/2024 | $5.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 7/3/2024 | $5.00 | Market Perform → Outperform | Leerink Partners |
| 4/2/2024 | $6.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 2/13/2024 | $23.00 → $7.00 | Outperform → Market Perform | Leerink Partners |
| 2/12/2024 | $25.00 → $7.00 | Outperform → In-line | Evercore ISI |
| 2/12/2024 | Outperform → Perform | Oppenheimer | |
| 2/12/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 1/4/2024 | $30.00 | Mkt Outperform | JMP Securities |
| 7/18/2022 | $22.00 | Outperform | Oppenheimer |
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
3 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
3 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-A12B - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
144 - AN2 Therapeutics, Inc. (0001880438) (Subject)
144 - AN2 Therapeutics, Inc. (0001880438) (Subject)
10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously
Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00
JMP Securities upgraded AN2 Therapeutics from Mkt Perform to Mkt Outperform and set a new price target of $6.00
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $7.00 from $23.00 previously
Evercore ISI downgraded AN2 Therapeutics from Outperform to In-line and set a new price target of $7.00 from $25.00 previously
Oppenheimer downgraded AN2 Therapeutics from Outperform to Perform
JMP Securities downgraded AN2 Therapeutics from Mkt Outperform to Mkt Perform
JMP Securities initiated coverage of AN2 Therapeutics with a rating of Mkt Outperform and set a new price target of $30.00
Oppenheimer resumed coverage of AN2 Therapeutics with a rating of Outperform and set a new price target of $22.00
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. Details of the events are as follows: 7th Annual Evercore HealthCONx Conference, December 3-5, 2024 Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, December 4 at 8:20am ET Oppenheimer's Movers in Rare Disease Summit, December 12, 2024 Members of management will be available for 1X1 meetings on Thursday, December 12, 2024 A webcast of the Ev
Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance when evaluated as continuous measures First drug candidate with statistically favorable patient reported outcome (PRO)-based improvement in treatment-refractory Mycobacterium avium Complex (TR-MAC) population Company plans to meet with FDA to gain alignment on a development path for epetraborole, including potentially reinitiating a Phase 3 clinical study, while advancing its boron chemistry pipeline Achieved 50% reduction in expenditures through strategic realignment of operations Cash, cash equivalents, and investments of $93.4 million a
Grant from the Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria. "We are appreciative of the Gates Foundation's continued support as we advance our joint effort to discover new drugs for tuberculosis and malaria, with the goal of combating drug resistance and shortening treatment duration for th
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. Details of the event is as follows: H.C. Wainwright 26th Annual Global Investment Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Tuesday, September 10 at 9:30am ET A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archiv
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all
Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30, 2024. "We reported results from the EBO-301 Phase 2/3 study in patients with treatment-refractory MAC lung disease last week and over the coming months will further analyze the data to determine next steps in NTM lung disease," said Eric Easom, Co-Founder, Chairman, President and CEO. "Despite this setback, we remain
EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron chemistry platform and ongoing pipeline programs Company restructuring and cost savings associated with discontinuation of the EBO-301 study expected to extend cash runway through 2027 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole on top of an optimized backgrou
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determined after review of unblinded Phase 2 data and discussions with the FDA Cash, cash equivalents, and investments of $118.1 million at March 31, 2024 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 202
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease On track to announce Phase 2 clinical data summer 2024 Cash and investments of $150.2 million at September 30, 2023; cash runway anticipated to fund operations through summer 2025 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023. "We are incredibly proud of the significant milestones achieved recently and over the p
Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease Expected initiation of Phase 3 portion of pivotal Phase 2/3 study in September AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023. "We're pleased with the accelerated pace of enrollment in our pivotal Phase 2/3 study evaluating epetraborole for treatment-refractory MAC lung disease and be
Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2023. "In the first quarter we continued to advance our pivotal Phase 2/3 trial evaluating epetraborole for treatment-refractory MAC lung disease with a total of nearly 80 clinical sites active worldwide. We are pleased with the momentum we're seeing in the Asia-Pacific region, particularly at
Approaching 60 clinical sites participating in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease to date Opened up sites in three additional countries -- Japan, South Korea, and Australia in addition to the U.S.; Japan has some of the highest rates of MAC lung disease in the world Activities underway to advance development of epetraborole for acute systemic melioidosis using non-dilutive funding AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fou
Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD) Multiple Phase 2a proof-of-concept (POC) clinical data readouts and Phase 2b clinical trial initiations expected in 2023 Operations well-funded through 2025 Company to host conference call today at 8:00 PM HKT / 8:00 AM ET DURHAM, N.C. and BEIJING, March 24, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across disease
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.
Gainers Kineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million. Brainstorm Cell (NASDAQ:BCLI) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million. Can Fite Biofarma (AMEX:
Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target from $7 to $2.
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197
JMP Securities analyst Roy Buchanan upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform and announces $6 price target.
Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.76) by 25 percent. This is a 6.56 percent increase over losses of $(0.61) per share from the same period last year.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for monday.com Ltd. (NASDAQ:MNDY) from $238 to $242. Keybanc analyst Jason Celino maintained an Overweight rating. monday.com shares dipped 10.1% to close at $212.01 on Monday. See how other analysts view this stock. Needham cut G1 Therapeutics, Inc. (NASDAQ:GTHX) price target from $14 to $12. Needham analyst Gil Blum maintained a Buy rating. G1 Therapeutics shares fell 1.1% to close at $4.48 on Monday. See how other analysts view this stock. Needham boosted the pri
Leerink Partners analyst Joseph Schwartz downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Market Perform and lowers the price target from $23 to $7.
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The S&P 500 also rose, gaining, 0.12% to 5,032.46. Check This Out: Caterpillar, Marathon Petroleum And More On CNBC's 'Final Trades' Leading and Lagging Sectors Energy shares rose by 1.1% on Monday. In trading on Monday, health care shares fell by 0.1%. Top Headline Martin Marietta Materials Inc (NYSE:MLM) disclosed a deal to acquire 20 active operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (BWI Southea
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the
AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)